NCT03620058View on ClinicalTrials.gov

CART22 Alone or in Combination With huCART19 for ALL

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

September 27, 2018

Primary Completion Date

January 31, 2036

Study Completion Date

January 31, 2036

Conditions
Chemotherapy Resistant Acute Lymphoblastic LeukemiaRefractory Acute Lymphoblastic Leukemia
Interventions
BIOLOGICAL

CART22-65s cells

Autologous T cells transduced with a lentiviral vector to express anti-CD22 scFv TCRz:41BB

BIOLOGICAL

huCART19 Cells

Autologous T cells transduced with lentiviral vector to express anti-CD19 scFv TCRζ:4-1BB

Trial Locations (1)

19104

University of Pennsylvania, Philadelphia

All Listed Sponsors
lead

University of Pennsylvania

OTHER